Search results for Demcizumab
Demcizumab Biosimilar – Anti-DLL4 mAb – Research Grade, ProteoGenix, PX-TA1289
Description of Demcizumab Biosimilar - Anti-DLL4 mAb - Research Grade General information on Anti-DLL4 [Homo sapiens] (Demcizumab) Monoclonal Antibody Demcizumab is investigated for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
Host
Reactivity
Applications
Conjugation
Demcizumab, Abbexa, abx831246
Demcizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting DLL4, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Demcizumab Biosimilar - Research Grade, ichor.bio, ICH5472
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Research Grade Demcizumab (HV571016), abinScience, HV571016
Host
Humanized
Reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Conjugation
Please provide the required information below so that we can quickly source your products.